Search research articles
Contact Us
Filters
Showing results (41-50 of 61) with videos related to
Page
of 7
Sort By:
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Der Urologe. Ausg. A
|
September 22, 2019
[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]
N Ortiz-Brüchle, M Muders, M Toma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
S M Dieter, C Heining, A Agaimy, et al.
ESMO Open
|
July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
C Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
ESMO Open
|
November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
C E Heilig, P Horak, S Kreutzfeldt, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 61) with videos related to
Sort By:
Page
of 7
ESMO Open
|
September 6, 2021
The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma
M Kirchner, K Kluck, R Brandt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 4, 2024
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M F Mosele, C B Westphalen, A Stenzinger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2025
Corrigendum to "Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group": [Ann Oncol 35 (2024) 588-606]
M F Mosele, C B Westphalen, A Stenzinger, et al.
Der Urologe. Ausg. A
|
September 22, 2019
[Status of the availability and use of next generation sequencing (NGS) in bladder cancer-a questionnaire within the uropathology working group]
N Ortiz-Brüchle, M Muders, M Toma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 28, 2020
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F Mosele, J Remon, J Mateo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)
S Peters, U Dafni, M Boyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinoma
S M Dieter, C Heining, A Agaimy, et al.
ESMO Open
|
July 15, 2025
Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany
C Kropf-Sanchen, A Rasokat, P Christopoulos, et al.
ESMO Open
|
November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial
C E Heilig, P Horak, S Kreutzfeldt, et al.
Lung Cancer (Amsterdam, Netherlands)
|
September 2, 2020
Risk stratification of EGFR<sup>+</sup> lung cancer diagnosed with panel-based next-generation sequencing
P Christopoulos, M Kirchner, J Roeper, et al.
Page
of 7